GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » ROE %

Optimind Pharma (XCNQ:OMND) ROE % : 0.00% (As of Nov. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Optimind Pharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Optimind Pharma's annualized net income for the quarter that ended in Nov. 2024 was C$-0.04 Mil. Optimind Pharma's average Total Stockholders Equity over the quarter that ended in Nov. 2024 was C$-0.04 Mil. Therefore, Optimind Pharma's annualized ROE % for the quarter that ended in Nov. 2024 was N/A%.

The historical rank and industry rank for Optimind Pharma's ROE % or its related term are showing as below:

XCNQ:OMND's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.82
* Ranked among companies with meaningful ROE % only.

Optimind Pharma ROE % Historical Data

The historical data trend for Optimind Pharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optimind Pharma ROE % Chart

Optimind Pharma Annual Data
Trend Feb22 Feb23 Feb24
ROE %
- -167.28 -547.16

Optimind Pharma Quarterly Data
Jun21 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -249.10 - - - -

Competitive Comparison of Optimind Pharma's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Optimind Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optimind Pharma's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Optimind Pharma's ROE % distribution charts can be found below:

* The bar in red indicates where Optimind Pharma's ROE % falls into.



Optimind Pharma ROE % Calculation

Optimind Pharma's annualized ROE % for the fiscal year that ended in Feb. 2024 is calculated as

ROE %=Net Income (A: Feb. 2024 )/( (Total Stockholders Equity (A: Feb. 2023 )+Total Stockholders Equity (A: Feb. 2024 ))/ count )
=-1.398/( (0.64+-0.129)/ 2 )
=-1.398/0.2555
=-547.16 %

Optimind Pharma's annualized ROE % for the quarter that ended in Nov. 2024 is calculated as

ROE %=Net Income (Q: Nov. 2024 )/( (Total Stockholders Equity (Q: Aug. 2024 )+Total Stockholders Equity (Q: Nov. 2024 ))/ count )
=-0.036/( (-0.039+-0.048)/ 2 )
=-0.036/-0.0435
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Nov. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Optimind Pharma  (XCNQ:OMND) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Nov. 2024 )
=Net Income/Total Stockholders Equity
=-0.036/-0.0435
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.036 / 0.108)*(0.108 / 0.216)*(0.216 / -0.0435)
=Net Margin %*Asset Turnover*Equity Multiplier
=-33.33 %*0.5*N/A
=ROA %*Equity Multiplier
=-16.67 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Nov. 2024 )
=Net Income/Total Stockholders Equity
=-0.036/-0.0435
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.036 / -0.036) * (-0.036 / -0.036) * (-0.036 / 0.108) * (0.108 / 0.216) * (0.216 / -0.0435)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1 * -33.33 % * 0.5 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Nov. 2024) net income data. The Revenue data used here is four times the quarterly (Nov. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Optimind Pharma ROE % Related Terms

Thank you for viewing the detailed overview of Optimind Pharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Optimind Pharma Business Description

Traded in Other Exchanges
N/A
Address
77 King Street West, Suite 3000, TD Centre, North Tower, PO Box 95, Toronto, ON, CAN, M5K 1G8
Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It is also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings.

Optimind Pharma Headlines

No Headlines